Experimental CCR5 antagonism with maraviroc in atherosclerosis-prone mice and preliminary data in humans suggest an anti-atherosclerotic effect of the drug. We assessed the impact of maraviroc treatment in persons living with HIV on subclinical indicators of atherosclerosis.
Maraviroc Intensification Modulates Atherosclerotic Progression in HIV-Suppressed Patients at High Cardiovascular Risk. A Randomized, Crossover Pilot Study
Francisci, DanielaConceptualization
;Pirro, MatteoConceptualization
;Schiaroli, Elisabetta;Mannarino, Massimo R;Cipriani, Sabrina;Bianconi, Vanessa;Alunno, Alessia;Bagaglia, Francesco;Bistoni, Onelia;Falcinelli, Emanuela;Bury, Loredana;Gerli, Roberto;Mannarino, Elmo;Baldelli, Franco
2019
Abstract
Experimental CCR5 antagonism with maraviroc in atherosclerosis-prone mice and preliminary data in humans suggest an anti-atherosclerotic effect of the drug. We assessed the impact of maraviroc treatment in persons living with HIV on subclinical indicators of atherosclerosis.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
